109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
青蒿素类抗疟疾药物的再利用：从抗疟疾到泛治疗药物的药理学前景与治疗挑战
Authors Wu D, Zeng H, Tan J, Xu Q, Khan FA, Pandupuspitasari NS, Yang S, Huang C
Received 6 June 2025
Accepted for publication 28 September 2025
Published 11 October 2025 Volume 2025:19 Pages 9199—9226
DOI https://doi.org/10.2147/DDDT.S545163
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Muzammal Hussain
Di Wu,1,* Hong Zeng,2,* Jiachen Tan,1 Qinzheng Xu,1,3 Faheem Ahmed Khan,4 Nuruliarizki Shinta Pandupuspitasari,5 Shengqiang Yang,2 Chunjie Huang1
1School of Medicine, Nantong University, Nantong, 226001, People’s Republic of China; 2School of Basic Medicine, Youjiang Medical University for Nationalities, Baise, 533000, People’s Republic of China; 3Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, 226001, People’s Republic of China; 4Research Center for Animal Husbandry, National Research and Innovation Agency, Jakarta Pusat, 10340, Indonesia; 5Faculty of Animal and Agricultural Sciences, Universitas Diponegoro, Semarang, 50275, Indonesia
*These authors contributed equally to this work
Correspondence: Shengqiang Yang, Email 1243884393@qq.com Chunjie Huang, Email goodlife.huang@ntu.edu.cn
Abstract: The sourcing of pharmaceutical agents from natural products remains a cornerstone of drug discovery. For millennia, herbal remedies have served as foundational therapeutic interventions, yet their mechanisms of action often remain elusive. Artemisinin (ART, or “Qinghaosu”) and its derivatives, collectively known as ARTs, exemplify this paradigm. Originating from traditional Chinese medicine, these well-established antimalarial compounds exhibit potent cytotoxicity, positioning them as promising anti-cancer agents. ARTs operate through multiple cancer cell-intrinsic mechanisms and demonstrate synergistic effects with conventional therapies, even against chemoresistant malignancies. Beyond oncology, the therapeutic portfolio of ART-based drugs is rapidly expanding. This review synthesizes recent advancements in the application of ARTs for treating various cancers, Alzheimer’s disease, and reproductive disorders. Furthermore, we explore the frontier of ART drug development, focusing on the rational design of ART-derived molecular hybrids and the engineering of nano-enabled delivery systems. These innovative strategies are pivotal for enhancing anti-cancer efficacy and achieving cancer-specific targeting. Ultimately, this work aims to guide the innovation of ART-based precision medicine, revitalizing the exploration and development of natural products in modern pharmacotherapy.
Keywords: artemisinin, malignancy, neurodegenerative disease, reproductive disorder, drug delivery
1School of Medicine, Nantong University, Nantong, 226001, People’s Republic of China; 2School of Basic Medicine, Youjiang Medical University for Nationalities, Baise, 533000, People’s Republic of China; 3Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, 226001, People’s Republic of China; 4Research Center for Animal Husbandry, National Research and Innovation Agency, Jakarta Pusat, 10340, Indonesia; 5Faculty of Animal and Agricultural Sciences, Universitas Diponegoro, Semarang, 50275, Indonesia
*These authors contributed equally to this work
Correspondence: Shengqiang Yang, Email 1243884393@qq.com Chunjie Huang, Email goodlife.huang@ntu.edu.cn
Abstract: The sourcing of pharmaceutical agents from natural products remains a cornerstone of drug discovery. For millennia, herbal remedies have served as foundational therapeutic interventions, yet their mechanisms of action often remain elusive. Artemisinin (ART, or “Qinghaosu”) and its derivatives, collectively known as ARTs, exemplify this paradigm. Originating from traditional Chinese medicine, these well-established antimalarial compounds exhibit potent cytotoxicity, positioning them as promising anti-cancer agents. ARTs operate through multiple cancer cell-intrinsic mechanisms and demonstrate synergistic effects with conventional therapies, even against chemoresistant malignancies. Beyond oncology, the therapeutic portfolio of ART-based drugs is rapidly expanding. This review synthesizes recent advancements in the application of ARTs for treating various cancers, Alzheimer’s disease, and reproductive disorders. Furthermore, we explore the frontier of ART drug development, focusing on the rational design of ART-derived molecular hybrids and the engineering of nano-enabled delivery systems. These innovative strategies are pivotal for enhancing anti-cancer efficacy and achieving cancer-specific targeting. Ultimately, this work aims to guide the innovation of ART-based precision medicine, revitalizing the exploration and development of natural products in modern pharmacotherapy.
Keywords: artemisinin, malignancy, neurodegenerative disease, reproductive disorder, drug delivery